The article discusses the potential for developing targeted epigenetic therapies by inhibiting specific protein-protein interactions. The focus is on the inhibition of methyl-dependent interactions, specifically with HP1 protein, which is involved in gene silencing and heterochromatin formation. The article describes a chemiluminescence-based assay that has been developed for identifying lead compounds that can block these interactions. It is hoped that these compounds can be developed into targeted therapies for cancer and neurological diseases. Is the molecule effective to this assay?